Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690648 | 0.79 | PDK2 (0.40) | GABRA1GABRB2PDK2HDAC4HTR7 | |
| SCHEMBL18663400 | 0.79 | PDK2 (0.40) | GABRA1GABRB2PDK2HDAC4HTR7 | |
| SCHEMBL19690654 | 0.77 | PDK2 (0.41) | GABRA1GABRB2PDK2HDAC4HTR7 | |
| SCHEMBL21046178 | 0.75 | PDK2 (0.34) | GABRA1GABRB2PDK2HTR7HTR2B | |
| SCHEMBL19690603 | 0.74 | KMT2A (0.34) | PDK2HDAC4CYP2D6TSHR | |
| SCHEMBL19690572 | 0.72 | PDK2 (0.34) | PDK2HTR7HTR2B | |
| SCHEMBL19690487 | 0.63 | PDK2 (0.47) | GABRA1GABRB2PDK2HDAC4HTR7 | |
| SCHEMBL18983054 | 0.62 | CLCN2 (0.56) | GABRA1GABRB2CLCN2ALOX15TSHR | |
| SCHEMBL19753235 | 0.60 | HDAC4 (0.61) | GABRA1GABRB2PDK2HDAC4CYP2D6 | |
| SCHEMBL1364609 | 0.59 | GABRA1 (0.68) | GABRA1GABRB2CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | RENQIU LIHE TECH LTD (CN) | 2019-06-06 | — | — | US | disclosed |
| US-20170355792-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | RENQIU LIHE TECH LTD (CN) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | COG2, GTF2I, POF1B | GABRA1 3986/4885GABRB2 3753/4885PDK2 3198/4885 |
| US-20170355792-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | COG2, COG7, COG4 | GABRA1 4432/4885GABRB2 4248/4885PDK2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.